The U.S. International Trade Commission opened investigations into Chinese government support and pricing practices in the biotech sector to assess whether state aid and pricing distortions disadvantaged American firms. BioCentury reported the probe could set the stage for tariffs or trade restrictions if investigators find evidence of market manipulation. The inquiry follows broader U.S. concerns about industrial policy in China and lists Western VC participation in Japan as separate dealflow context.